diastereoisomers (210 mg, 674 µmol, 77%, dr 94 : 6 by 1H
NMR). Major diastereoisomer: δH (500 MHz, CDCl3), 0.66
(3H, t, J 7.4, CH(OEt)CH2CH3), 1.10 (3H, d, J 6.7, NCHCH3),
1.14 (3H, t, J 7.0, OCH2CH3), 1.49–1.56 (1H, m, CH(OEt)-
CH2CH3), 1.68–1.75 (1H, m, CH(OEt)CH2CH3), 2.67 (1H,
quin, J 6.7, NCHCH3), 3.20–3.26 (1H, m, CH(OEt)Et), 3.38–
3.43 (1H, m, OCH2CH3), 3.43 (2H, d, J 14.1, N(CH2Ph)2),
3.51–3.58 (1H, m, OCH2CH3), 3.72 (2H, d, J 13.8, N(CH2Ph)2),
7.13–7.38 (10H, m, Ph); δC (125 MHz, CDCl3), 8.4 (CH-
(OEt)CH2CH3), 9.0 (NCHCH3), 15.7 (OCH2CH3), 24.0
(CH(OEt)CH2CH3), 54.4 (N(CH2Ph)2), 54.9 (NCHCH3), 65.5
(OCH2CH3), 83.1 (CH(OEt)Et), 126.7 (Ph), 128.1 (Ph), 128.8
(Ph), 140.4 (Ph); mixture of diastereoisomers (94 : 6): [α]D
ϩ14.5 (CHCl3, c 1.1); IR (neat), νmax/cmϪ1 2971, 2932, 2874,
1494, 1453, 1116, 1075, 909, 735, 698; MS (EI) m/z 311 (Mϩ,
0.5%), 296 (1.4), 225 (20), 224 (100), 91 (94).
(89 : 11): mp 68–71 ЊC; [α]D ϩ60.0 (CHCl3, c 1.0); IR (neat),
νmax/cmϪ1 2976, 1698, 1455, 1266, 1153, 1093, 737, 701; MS (ES)
m/z 421 (Mϩ, 0.1%), 309 (10), 280 (10), 253 (24), 252 (82), 92
(17), 91 (100).
1-((1R,2S )-2-(N,N-Dibenzylamino)-1-ethoxypropyl)-1H-pyr-
imidine-2,4-dione, 37 (R ؍
Me). Typical procedure B was used
with, TMSOTf (464 µl, 570 mg, 2.57 mmol), 2-(N,N-dibenzyl)-
aminopropanal diethyl acetal (286 mg, 873 µmol), and bis(O-
trimethylsilyl)uracil (438 mg, 1.71 mmol). The product was
purified by silica gel flash chromatography (eluent: gradient of
petroleum ether/ethyl acetate/triethylamine 69.5 : 30 : 0.5 to
ethyl acetate) to yield the uracil derivative 37 (R = Me) as colour-
less needles and an inseparable mixture of two diastereoisomers
(240 mg, 610 µmol, 71%, dr 55 : 45 by 1H NMR); major
diastereoisomer (1R,2S): δH (500 MHz, CDCl3), 1.20 (3H, d,
J 7.0, NCHCH3), 1.24 (3H, t, J 7.0, OCH2CH3), 2.96–3.02 (1H,
m, NCHCH3), 3.41 (2H, d, J 13.8, N(CH2Ph)2), 3.48 (2H, q,
J 7.0, OCH2CH3), 4.01 (2H, d, J 13.8, N(CH2Ph)2), 5.41 (1H, d,
J 4.4, CH(OEt)N), 5.74 (1H, d, J 8.0, uracil-CH ), 7.18–7.31
(10H, m, Ph), 7.44 (1H, d, J 8.0, uracil-CH ); δC (125 MHz,
CDCl3), 9.4 (NCHCH3), 14.8 (OCH2CH3), 54.3 (NCHCH3),
55.3 (N(CH2Ph)2), 66.0 (OCH2CH3), 89.1 (CH(OEt)N), 100.7
(uracil-CH), 127.0 (Ph), 128.4 (Ph), 128.5 (Ph), 139.5 (Ph),
141.1 (uracil-CH), 150.2 (uracil-CO), 163.2 (uracil-CO); minor
diastereoisomer (1S,2S): δH (500 MHz, CDCl3), 1.13 (3H, t,
J 7.0, OCH2CH3), 1.26 (3H, d, J 6.5, NCHCH3), 2.84–2.90
(1H, m, NCHCH3), 3.28 (2H, d, J 13.2, N(CH2Ph)2), 3.45 (1H,
dq, J 9.2, 7.0, OCH2CH3), 3.52 (1H, dq, J 9.2, 7.0, OCH2CH3),
3.72 (2H, d, J 13.2, N(CH2Ph)2), 5.51 (1H, d, J 8.0, uracil-CH ),
5.73 (1H, d, J 9.1, CH(OEt)N), 6.58 (1H, d, J 8.0, uracil-CH ),
7.18–7.31 (10H, m, Ph); δC (125 MHz, CDCl3), 8.4 (NCHCH3),
14.8 (OCH2CH3), 53.9 (NCHCH3), 55.1 (N(CH2Ph)2), 65.1
(OCH2CH3), 85.7 (CH(OEt)N), 102.3 (uracil-CH), 127.2
(Ph), 128.3 (Ph), 129.0 (Ph), 138.9 (Ph), 140.3 (uracil-CH),
151.4 (uracil-CO), 163.0(uracil-CO); mixture of diastereo-
isomers (55 : 45): mp 48–51 ЊC; [α]D ϩ8.60 (CHCl3, c 1.4);
IR (neat), νmax/cmϪ1 3190, 3061, 2977, 2937, 2808, 1699, 1495,
1452, 1385, 1265, 1151, 1085, 809, 743, 701; MS (EI) m/z
392 (Mϩ, 0.2%), 281 (5), 225 (39), 224 (100), 181 (17),
91 (99); HRMS (ES): 416.1964; calculated for C23H27N3O3Na:
416.1950.
1-((1R,2S )-2-(N,N-Dibenzylamino)-1-ethoxy-3-phenyl-
propyl)-1H-pyrimidine-2,4-dione, 37 (R ؍
Bn). Typical pro-
cedure B was used with TMSOTf (179 µl, 220 mg, 989 µmol),-2-
(N,N-dibenzylamino)-3-phenylpropanal diethyl acetal (133 mg,
330 µmol), and bis(O-trimethylsilyl)uracil (169 mg, 660 µmol).
The product was purified by silica gel flash chromatography
(eluent: gradient of petroleum ether/ethyl acetate/triethyl-
amine 79.5 : 20 : 0.5–59.5 : 40 : 0.5) to yield the uracil derivative
37 (R = Bn) as colourless plates and a single diastereoisomer
(109 mg, 232 µmol, 70%, de >98%). Mp 77–79 ЊC; [α]D ϩ63.3
(CHCl3, c 1.2); δH (500 MHz, CDCl3), 1.24 (3H, J 7.0,
OCH2CH3), 2.91 (1H, dd, J 14.8, 11.2, NCHBn), 3.19–3.24
(2H, m, NCH(CH2Ph)), 3.33 (1H, dq, J 9.5, 7.0, OCH2CH3),
3.45 (1H, dq, J 9.5, 7.0, OCH2CH3), 3.56 (2H, d, J 13.7,
N(CH2Ph)2), 4.14 (2H, d, J 13.7, N(CH2Ph)2), 5.32 (1H, d,
J 4.0, CH(uracil )OEt), 5.65 (1H, dd, J 8.0, 2.2, uracil-CH ),
7.11–7.34 (15H, m, Ph), 7.37 (1H, d, J 8.0, uracil-CH ); δC (125
MHz, CDCl3), 15.0 (OCH2CH3), 31.1 (NCH(CH2Ph)), 55.6
(N(CH2Ph)2), 60.1 (NCH(CH2Ph)), 65.8 (OCH2CH3), 87.2
(CH(uracil )OEt), 100.4 (uracil-CH), 126.6 (Ph), 127.2 (Ph),
128.4 (Ph), 128.5 (Ph), 128.7 (Ph), 128.9 (Ph), 138.5 (Ph), 139.2
(Ph), 141.2 (uracil-CH), 149.8 (uracil-CO), 163.2 (uracil-CO);
IR (neat), νmax/cmϪ1 3060, 3029, 2977, 1699, 1495, 1456, 1102,
732, 699; MS (EI) m/z 469 (Mϩ, 0.2%), 378 (17), 301 (56), 300
(93), 181 (13), 91 (100); HRMS (ES): 492.2273; calculated for
C29H31N3O3Na: 492.2263; structure confirmed by X-ray crystal-
lographic analysis10 and data has been deposited with the
Cambridge Crystallographic Data Centre as supplementary
publication number CCDC 153574.
1-((1R,2S )-2-(N,N-Dibenzylamino)-1-ethoxy-3-phenyl-
propyl)-1H-pyridin-2-one, 38 (R ؍
Bn). Typical procedure B was
used with TMSOTf (452 µl, 555 mg, 2.50 mmol), 2-(N,N-
dibenzylamino)-3-phenylpropanal diethyl acetal (336 mg, 833
µmol), and 2-trimethylsilyloxypyridine (279 mg, 1.67 mmol).
The product was purified by silica gel flash chromatography
(eluent: gradient of petroleum ether/ethyl acetate/triethylamine
69 : 30 : 1–49 : 50 : 1) to yield 38 (R = Bn) as colourless plates
and an inseparable mixture of two diastereoisomers (340 mg,
715 µmol, 89%, dr 95 : 5 by 1H NMR). Major diastereoisomer:
δH (500 MHz, CDCl3), 1.23 (3H, J 7.0, OCH2CH3), 2.81 (1H,
dd, J 13.9, 8.4, NCH(CH2Ph)), 3.11 (1H, dd, J 13.9, 6.3,
NCH(CH2Ph)), 3.28 (1H, ddd, J 8.4, 6.3, 5.2, NCH(CH2Ph)),
3.37 (1H, q, J 7.0, OCH2CH3), 3.38 (1H, q, J 7.0, OCH2CH3),
3.67 (2H, d, J 13.9, N(CH2Ph)2), 4.12 (2H, d, J 13.9,
N(CH2Ph)2), 5.92 (1H, d, J 5.2, CH(py)OEt), 6.17 (1H, dt,
J 1.3, 6.7, py5-CH ), 6.35 (1H, ddd, J 9.1, 1.3, 0.6, py3-CH ),
7.04 (1H, dd, J 6.8, 1.3, py4-CH ), 7.15–7.28 (15H, m, Ph), 7.46
(1H, ddd, J 7.0, 2.1, 0.6, py6-CH ); δC (125 MHz, CDCl3), 15.2
(OCH2CH3), 31.8 (NCH(CH2Ph)), 55.3 (N(CH2Ph)2), 60.4
(NCH(CH2Ph)), 65.3 (OCH2CH3), 86.6 (CH(py)OEt), 105.0
(py5-CH), 120.6 (py3-CH), 126.1 (py4-CH), 126.8 (Ph), 128.2
(Ph), 128.3 (Ph), 128.4 (Ph), 129.1 (Ph), 133.8 (Ph), 138.9 (Ph),
139.1 (Ph), 139.6 (py6-CH), 162.5 (py2-CO); mixture of
diastereoisomers (95 : 5): [α]D ϩ150.0 (CHCl3, c 0.8); IR (neat),
νmax/cmϪ1 3063, 3027, 2977, 1660, 1587, 1538, 1495, 1454, 1139,
1103, 1077, 910, 734, 699; MS (EI) m/z 377 (M ϩ 1, 45%), 282
1-((1R,2S )-2-(N,N-Dibenzylamino)-1-ethoxy-3-methylbutyl)-
1H-pyrimidine-2,4-dione, 37 (R ؍
Pri). Typical procedure B was
used with TMSOTf (505 µl, 621 mg, 2.79 mmol),-2-(N,N-
dibenzyl)amino-3-methylbutanal diethyl acetal (331 mg, 931
µmol), and bis(O-trimethylsilyl)uracil (477 mg, 1.86 mmol).
The product was purified by silica gel flash chromatography
(eluent: gradient of petroleum ether/ethyl acetate/triethylamine
69.5 : 30 : 0.5 to ethyl acetate) to yield the uracil derivative 37 (R
= Pri) as a colourless plates and an inseparable mixture of two
1
diastereoisomers (304 mg, 721 µmol, 76%, dr 89 : 11 by H
NMR); major diastereoisomer (1R,2S): δH (500 MHz, CDCl3),
1.00 (3H, d, J 6.7, NCHCH(CH3)2), 1.17 (3H, d, J 6.8, NCH-
CH(CH3)2), 1.24 (3H, t, J 7.0, OCH2CH3), 2.16–2.23 (1H, m,
NCHCH(CH3)2), 2.68 (3H, dd, J 6.9, 4.2, NCHCH(CH3)2),
3.42–3.52 (2H, m, OCH2CH3), 3.74 (2H, d, J 13.1, N(CH2Ph)2),
4.07 (2H, d, J 13.1, N(CH2Ph)2), 5.66 (1H, d, J 8.0, uracil–CH ),
5.68 (1H, d, J 4.2, CH(OEt)N), 7.15–7.31 (10H, m, Ph), 7.40
(1H, d, J 8.0, uracil–CH ); δC (125 MHz, CDCl3), 15.1 (NCH-
CH(CH3)2), 21.2 (NCHCH(CH3)2), 22.1 (OCH2CH3), 27.8
(NCHCH(CH3)2), 56.5 (N(CH2Ph)2), 63.2 (NCHiPr), 65.4
(OCH2CH3), 87.3 (CH(OEt)N), 100.9 (uracil–CH), 127.1 (Ph),
128.3 (Ph), 129.2 (Ph), 139.5 (Ph), 141.1 (uracil–CH), 150.2
(uracil–CO), 163.6 (uracil–CO); Mixture of diastereoisomers
O r g . B i o m o l . C h e m . , 2 0 0 3 , 1, 8 3 4 – 8 4 9
847